The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS)

Internal Medicine

Volumn 48, Issue 14, 2009, Pages 1193-1199

  Bilgir, Oktay ^a   Kebapcilar, Levent ^a   Taner, Cuneyt ^b   Bilgir, Ferda ^c   Kebapcilar, Ayse ^b   Bozkaya, Giray ^a   Yildiz, Yasar ^a   Yuksel, Arif ^a   Sari, Ismail ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Turkey)

^b Izmir Tepecik Training and Research Hospital   (Turkey)

^c SSK Buca Hospital   (Turkey)

Author keywords

Cellular adhesion molecules; Metformin; PCOS

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; DIANE; DIANE NOVA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 6; L SELECTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PRASTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANOVULATION; ARTICLE; BODY MASS; CELL ADHESION; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MONOTHERAPY; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CYPROTERONE ACETATE; DRUG THERAPY, COMBINATION; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 70349529613     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2177     Document Type: Article

References (33)

1. Alexander RW. Inflamation and coronary artery disease. N Eng J Med 331: 468-469, 1994.
2. Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159: 1104-1109, 1999.
3. Lee CD, Folsom AR, Nieto FJ, et al. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and white men and women. Am J Epidemiol 154: 758-764, 2001.
4. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103: 1405-1410, 2001.
5. Moran LJ, Noakes M, Clifton PM, Wittert GA, Belobrajdic DP, Norman RJ. C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 92: 2944-2951, 2007.
6. Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, Szymczak J, Bednarek-Tupikowska G, Demissie M. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol 24: 378-384, 2008.
7. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Human Reproduc 21: 1426-1431, 2006.
8. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41-47, 2004.
9. Zwirska-Korczala K, Sodowski K, Konturek SJ, et al. Postprandial response of ghrelin and pindices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. J Physiol Pharmacol 59 (Suppl 2): 161-178, 2008.
10. Heutling D, Schulz H, Nickel I, et al. Asymmetrical dimethylarginine, inflamatory and metabolic parameters in woman with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 93: 82-90, 2008.
11. Bahceci M, Tuzcu A, Canoruc N, et al. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovary syndrome and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Horm Res 62: 283-287, 2004.
12. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, et al. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 89: 806-811, 2004.
13. Orio F Jr, Palomba S, Cascella T, et al. The increase of leucocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 90: 2-5, 2005.
14. De Jager J, Kooy A, Lehert PH, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflamatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 257: 100-109, 2005.
15. Orio F Jr, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 90: 6072-6076, 2005.
16. O'Brain KD, McDonald TO, Chait A, et al. Neovascular expression of S E-selectin, intracellular adhesion molecule-1, and vascular adhesion molecule-1 in human atherosclerosis and their relation to intimal leucocyte content. Circulation 93: 672-682, 1996.
17. Katayama Y, Hidalgo A, Furie BC, et al. PSGL-1 partipicates in sE-selectin mediated progenitor homing to bone marrow: evidence for cooperation between sE-selectin ligands and alpha4 integrin. Blood 102: 2060-2067, 2003.
18. Steegmaier M, Levinovitz A, Isenmann S, et al. The S E-selectin ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature 373: 615-620, 1995.
19. Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 26: 611-617, 2006.
20. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 47: 1183-1188, 2006.
21. Ryysy L, Yki-Jarvinen H. Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes. Diabetes Care 24: 549-554, 2001.
22. De Jager J, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 257: 100-109, 2005.
23. Lund SS, Tarnow L, Stehouwer CD, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 158: 631-641, 2008.
24. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 53: 159-164, 2004.
25. Kautzky-Willer A, Tura A, Winzer C, et al. Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. Diabetes Obes Metab 8: 561-567, 2006.
26. Tatsumi H, Kitawaki J, Tanaka K, Hosoda T, Honjo H. Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins. Maturitas 42: 287-294, 2002.
27. Hemelaar M, van der Mooren MJ, van Baal WM, Schalkwijk CG, Kenemans P, Stehouwer CD. Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women. Menopause 12: 526-535, 2005.
28. Seeger H, Petersen G, Schulte-Wintrop E, Teichmann AT, Mueck AO. Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function. Int J Clin Pharmacol Ther 40: 150-157, 2002.
29. Kernohan AF, Spiers A, Sattar N, et al. Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes. Diab Vasc Dis Res 1: 82-88, 2004.
30. Goudev A, Georgiev D, Koycheva N, Manasiev N, Kyurkchiev S. Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women. Maturitas 43: 49-53, 2002.
31. Farzati A, Esposito K, Colacurci N, Fornaro F, Chiantera V, Farzati B. Effects of transdermal hormone replacement therapy on levels of soluble P- and E-selectin in postmenopausal healthy women. Fertil Steril 77: 476-480, 2002.
32. Matsushita K, Yatsuya H, Tamakoshi K, et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 26: 871-876, 2006.
33. Nishida M, Moriyama T, Sugita Y, Yamauchi-Takihara K. Interleukin-10 associates with adiponectin predominantly in subjects with metabolic syndrome. Circ J 71: 1234-1238, 2007.